Recent meta-analyses have revealed that thyroid cancers with concurrent BRAF V600E or RAS and TERT promoter mutations were associated with increased tumor aggressiveness compared to those harboring BRAF V600E, RAS, or TERT promoter mutations alone [21]. The gene discussed is BRAF; the disease is thyroid cancer.